About
Cell Therapy for Immuno-Oncology
Areas of Focus
Categories
Stem Cell & Cellular Therapy
Team (20)
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
194
By Phase
PHASE1: 5PHASE2: 2PHASE1/PHASE2: 1
By Status
COMPLETED: 5ACTIVE_NOT_RECRUITING: 2TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT04739527Collaborator
Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment
PHASE1Active, not recruiting
17 participants
Started: Jun 10, 2021 · Completed: Jun 1, 2026
NCT03735290Lead Sponsor
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer
PHASE1Terminated
21 participants
Started: Jan 14, 2019 · Completed: Dec 3, 2021
NCT03697707Lead Sponsor
Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia
PHASE2Active, not recruiting
20 participants
Started: Oct 15, 2018 · Completed: Dec 31, 2025
NCT02686944Lead Sponsor
A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors
PHASE1Completed
6 participants
Started: Jun 1, 2016 · Completed: May 10, 2019
NCT02432846Lead Sponsor
Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
PHASE2Completed
88 participants
Started: Apr 30, 2015 · Completed: Jan 31, 2021
Locations (1)
Headquarters
Stockholm, Sweden
Map
Loading map...